- Home
- PCRX vs JBGS Comparison
PCRX vs JBGS Comparison
Compare PCRX & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- JBGS
- Stock Information
- Founded
- PCRX 2006
- JBGS 2016
- Country
- PCRX United States
- JBGS United States
- Employees
- PCRX N/A
- JBGS N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- JBGS Real Estate Investment Trusts
- Sector
- PCRX Health Care
- JBGS Real Estate
- Exchange
- PCRX Nasdaq
- JBGS Nasdaq
- Market Cap
- PCRX 1.2B
- JBGS 1.3B
- IPO Year
- PCRX 2011
- JBGS 2017
- Fundamental
- Price
- PCRX $22.90
- JBGS $18.43
- Analyst Decision
- PCRX Buy
- JBGS Sell
- Analyst Count
- PCRX 8
- JBGS 2
- Target Price
- PCRX $28.38
- JBGS $16.00
- AVG Volume (30 Days)
- PCRX 545.0K
- JBGS 1.5M
- Earning Date
- PCRX 07-29-2025
- JBGS 07-29-2025
- Dividend Yield
- PCRX N/A
- JBGS 3.82%
- EPS Growth
- PCRX N/A
- JBGS N/A
- EPS
- PCRX N/A
- JBGS N/A
- Revenue
- PCRX $702,772,000.00
- JBGS $520,825,000.00
- Revenue This Year
- PCRX $7.54
- JBGS N/A
- Revenue Next Year
- PCRX $10.78
- JBGS $2.71
- P/E Ratio
- PCRX N/A
- JBGS N/A
- Revenue Growth
- PCRX 3.08
- JBGS N/A
- 52 Week Low
- PCRX $11.16
- JBGS $13.28
- 52 Week High
- PCRX $27.64
- JBGS $18.86
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- JBGS 63.92
- Support Level
- PCRX $22.82
- JBGS $16.78
- Resistance Level
- PCRX $23.83
- JBGS $17.64
- Average True Range (ATR)
- PCRX 0.74
- JBGS 0.58
- MACD
- PCRX -0.02
- JBGS 0.06
- Stochastic Oscillator
- PCRX 6.22
- JBGS 86.85
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.